• FDA OKs Revefenacin for COPD

    6 monthes ago - By Medscape

    Revefenacin, a long-acting muscarinic antagonist, is the first once-daily nebulized bronchodilator approved for chronic obstructive pulmonary disease in the US.
    FDA Approvals
    Read more ...


  • FDA approves Yupelri for adults with COPD

    6 monthes ago - By Healio

    The FDA has approved Yupelri for the maintenance treatment of adult patients with chronic obstructive pulmonary disease, according to a press release.
    Yupelri is a long-acting muscarinic antagonist that helps improve lung function in patients with COPD.
    Last year, the once-daily nebulized bronchodilator demonstrated positive results in a phase 3 trial. In 1,055 patients with COPD, revefenacin was well tolerated with no new safety issues reported. It also demonstrated clinically meaningful improvements in moderate-to-sever COPD after 12 weeks compared to
    Read more ...